175.70 -1.16 (-0.66%)
After hours: 7:36PM EDT
|Bid||171.00 x 800|
|Ask||176.00 x 800|
|Day's Range||175.04 - 178.42|
|52 Week Range||136.50 - 183.39|
|PE Ratio (TTM)||109.65|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride scholarship to pursue an education in science, technology, engineering, art or math (STEAM) at any University of Massachusetts campus.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to
NEW YORK, Aug. 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Immunomedics, ...
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF in this population. ORKAMBI oral granules are available in two dosage strengths (lumacaftor 100mg/ivacaftor 125mg and lumacaftor 150mg/ivacaftor 188mg) for weight-based dosing. ORKAMBI oral granules should be available for fulfillment within 2 to 4 weeks.
If approved, SYMKEVI® will be Vertex’s third medicine to treat the CFTR protein defect in patients with cystic fibrosis – a rare life-shortening disease
-Second-quarter 2018 total CF product revenues of $750 million, a 46% increase compared to $514 million in the second quarter of 2017-
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 25, 2018 at 4:30 PM ...
Stock Research Monitor: TPIV, VCEL, and VRTX LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration . On Tuesday, July 24, ...
Vertex Pharmaceuticals Incorporated (VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Acceleron Pharma and Vertex Pharmaceuticals both saw big gains on Friday on separate positive catalysts last week. Acceleron and Celgene reported strong results ...
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Health Canada approved PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or who have one copy of the F508del mutation and one of the following mutations in the CFTR gene: P67L, D110H, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T. “This approval is an important milestone in our journey to enhance and expand treatment options for people living with CF,” said Reshma Kewalramani, M.D., Executive Vice President and Chief Medical Officer at Vertex.
Vertex Pharmaceuticals Incorporated today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize for “transformative discoveries in the fields of genetics, physiology, pulmonology and pharmacology that led to the development of life-altering precision-targeted treatments for the devastating multi-organ disease cystic fibrosis ...
Vertex Pharmaceuticals Incorporated (VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines, San Diego. The San Diego site is one of Vertex’s three global research hubs, and is where the Company’s three breakthrough cystic fibrosis (CF) medicines were discovered. “Our researchers in San Diego have spent the last 20 years doing what was once thought impossible – developing the first medicines that treat the underlying cause of cystic fibrosis,” said Dr. David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. “We are delighted that people with CF in Sweden will join the thousands of others around the world who are already benefitting from our CF medicines,” said Simon Bedson, International General Manager at Vertex.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company’s new dollar-for-dollar matching gift program. The funds demonstrate the Company’s long-term commitment to giving back and to supporting employees’ deep commitment to strengthening their communities. The matching gift program launched on November 28, 2017 and was created to extend the impact of employee donations to qualified nonprofit organizations.
Vertex Pharmaceuticals Incorporated (VRTX) today announced 10 scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 41st European Cystic Fibrosis Conference taking place June 6-9, 2018, in Belgrade, Serbia. Collectively, the data support the potential disease-modifying benefits of treating the underlying cause of CF and Vertex’s progress toward enhancing and expanding treatment options for all people living with CF. Data from the ongoing Phase 3, open-label ARRIVAL study presented at an oral session and published online today in The Lancet Respiratory Medicine show that treatment with KALYDECO® (ivacaftor) resulted in substantial decreases in mean sweat chloride as well as improvements to multiple efficacy endpoints, suggesting the potential to preserve pancreatic function and modify the course of CF beginning in children as young as one year of age.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET (2:40 p.m. PT). The audio portion of management’s remarks will be available live through Vertex’s website, www.vrtx.com in the “Investors” section under the “News and Events” page. A replay of the conference webcast will be archived on the company’s website.
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the treatment of sickle cell disease pending the resolution of certain questions that will be provided by the FDA as part of its review of the IND. The IND was submitted to the FDA in April to support the planned initiation of a Phase 1/2 trial in the U.S. in adult patients with sickle cell disease. CRISPR and Vertex expect to obtain additional information on the FDA’s questions in the near future and plan to work rapidly with the FDA toward a resolution.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program. Each of the 80 scholarship recipients will be awarded $5,000 for the 2018-2019 academic year. The Vertex All in for CF Scholarship program was established in 2017 to help people living with cystic fibrosis (CF) and their immediate family members pursue two-year, four-year or graduate degrees.
LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free research report on Gilead Sciences, Inc. (NASDAQ: GILD). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=GILD as the Company's latest news hit the wire.
Vertex Pharmaceuticals Incorporated today reported consolidated financial results for the first quarter ended March 31, 2018 and reviewed recent progress with its approved and investigational medicines.
Vertex Pharmaceuticals Incorporated today announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis .
Vertex Pharmaceuticals Incorporated will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m.